Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.?
| Revenue (Most Recent Fiscal Year) | $0.02M |
| Net Income (Most Recent Fiscal Year) | $-190.89M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.57 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -3710.63% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -50.04% |
| Return on Assets (Trailing 12 Months) | -36.74% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.72 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.72 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.26 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.87 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.67 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 345.49M |
| Free Float | 299.89M |
| Market Capitalization | $685.80M |
| Average Volume (Last 20 Days) | 4.78M |
| Beta (Past 60 Months) | 0.47 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 83.63% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |